Category Archives: Stem Cell Therapy

A New Research on the Global Animal Stem Cell Therapy Market was conducted across a variety of businesses in various regions to produce a worthy report for our clienteles. This study is a perfect mixture of qualitative and quantifiable information highlighting key market expansions, industry and competitors challenges in gap analysis and new opportunities and may be trending in the Animal Stem Cell Therapy market. Some are part of the coverage and are the core and emerging players being profiled are specified in this report.

Some of major Animal Stem Cell Therapy market players are:

Medivet Biologics LLCVETSTEM BIOPHARMAJ-ARMU.S. Stem Cell, IncVetCell TherapeuticsCelavet Inc.Magellan Stem CellsKintaro Cells PowerAnimal Stem CareAnimal Cell TherapiesCell Therapy SciencesAnimacel

Request for sample copy of the Animal Stem Cell Therapy Market report @: https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268 #request_sample

Import and export policies that can have an immediate impact on the global Animal Stem Cell Therapy market. This study includes export-import related chapters for all relevant companies dealing with the Animal Stem Cell Therapy market and related profiles and provides valuable data in terms of finances, product portfolio, and investment planning and marketing and business strategy. The study is a collection of primary and secondary data that covers valuable information from the key suppliers of the marketplace. The forecast is based on data from 2014 to the current date and forecasts until 2024, easy to study other graphs and tables People watching for major industry data in easily available documents.

The report is sub-segmented Based on Product Type:

DogsHorsesOthers

The report is sub-segmented Based on Product Applications:

Veterinary HospitalsResearch Organizations

Quantifiable data:

Market Data Breakdown by Key Geography, Type & Application / End-User

By type (past and forecast)

Animal Stem Cell Therapy Market-Specific Applications Sales and Growth Rates (Historical & Forecast)

Animal Stem Cell Therapy revenue and growth rate by market (history and forecast)

Animal Stem Cell Therapy market size and growth rate, application and type (past and forecast)

Sales revenue, volume and Y-O-Y growth rate (base year) of Animal Stem Cell Therapy market

Qualitative data:

Includes factors affecting or influencing market dynamics and market growth. To list some names in related sections

Industry overview

Global Animal Stem Cell Therapy market growth driver

Global Animal Stem Cell Therapy market trend

Incarceration

Animal Stem Cell Therapy Market Opportunity

Market entropy ** [specially designed to emphasize market aggressiveness]

Fungal analysis

Porter Five Army Model

Inquire Here For Queries Or Report Customization: : https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268 #inquiry_before_buying

Customized specific regional and country-level reports for the following areas.

South America Animal Stem Cell Therapy Market (Brazil, Argentina)

The Middle East & Africa Animal Stem Cell Therapy Market (South Africa, Saudi Arabia)

Europe Animal Stem Cell Therapy Market (Spain, U.K., Italy, Germany, Russia, France)

North America Animal Stem Cell Therapy Market (U.S., Mexico, Canada)

Asia-Pacific Animal Stem Cell Therapy Market (China, Japan, India, Southeast Asia)

The research provides answers to the following key questions:

1) Who are the key Top Competitors in the Global Animal Stem Cell Therapy Market?

2) What is the expected Market size and growth rate of the Animal Stem Cell Therapy market for the period 2019-2024?

3) Which Are The Main Key Regions Cover in Reports?

4) Can I include additional segmentation / market segmentation?

Some of the Points cover in Global Animal Stem Cell Therapy Market Research Report is:

Table of Content:

Chapter One: Animal Stem Cell Therapy Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Animal Stem Cell Therapy Market Competition, by Players

Chapter Four: Global,Animal Stem Cell Therapy Market Size by Regions

Chapter Five: North America Animal Stem Cell Therapy Revenue by Countries

Chapter Six: Europe Animal Stem Cell Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Animal Stem Cell Therapy Revenue by Countries

Chapter Eight: South America Animal Stem Cell Therapy Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Animal Stem Cell Therapy by Countries

Chapter Ten: Global Animal Stem Cell Therapy Market Segment by Type

Chapter Eleven: Global Animal Stem Cell Therapy Market Segment by Application

Chapter Twelve: Global Animal Stem Cell Therapy Market Size Forecast (2019-2024)

Get Exclusive Discount on This Report:

Customization of the Report: Customization can be provided on the basis of clients requirements. Get in touch with our sales team ([emailprotected]).

Browse full report @ https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268 #table_of_contents

Follow this link:
Global Animal Stem Cell Therapy Market- Qualitative Analysis, Key Manufacturers, Advance Technology Research, Innovation in Technology and Forecast to...

Dublin, Dec. 31, 2019 (GLOBE NEWSWIRE) -- The "Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The stroke therapeutics market analysis considers sales from both ischemic stroke and hemorrhagic stroke types. The analysis also considers the sales of stroke therapeutics in Asia, Europe, North America, and ROW. In 2018, the ischemic stroke therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as availability of patient assistance programs will play a significant role in the ischemic stroke therapeutics segment to maintain its market position. Also, the global stroke therapeutics market report looks at factors such as high-risk factors for stroke, strong pipeline, and growth of the geriatric population. However, high level of genericization in the market, availability of substitutes, and clinical trial failures may hamper the growth of the stroke therapeutics industry over the forecast period.

Globally, stroke is the second-leading cause of death among adults. The high prevalence of stroke is attributed to the increase in the incidence of ischemic strokes and hemorrhagic strokes, mainly because of the increasing presence of high-risk factors over the years. The major risk factors such as high blood pressure, high cholesterol levels and obesity, heart diseases, and diabetes are increasing the number of strokes that results in several deaths across the world. The risk of stroke also increases due to excessive smoking and alcohol consumption. Such risk factors will lead to the expansion of the global stroke therapeutics market at a CAGR of almost 5% during the forecast period.

The global stroke therapeutics market is expected to benefit from the development of novel therapies, such as stem cell therapies. Owing to the high prevalence of stroke, there is a huge need for safe and innovative novel therapies to treat stroke. Therefore, several companies are developing novel drugs for the treatment of stroke. The development of stem cell therapy will have a major impact on upcoming stroke therapeutics, as it has fewer side effects and regenerative properties. Some of the other novel drugs currently under various stages of development in the stroke therapeutics market are PSD-95 antagonist NA-1 developed by NoNO and 3K3A-APC developed by ZZ Biotech LLC. Such development of novel therapies with fewer side effects is expected to have a positive impact on the overall market growth.

With the presence of several major players, the global stroke therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading stroke therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi.

Also, the stroke therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPEPART 04: MARKET SIZINGPART 05: FIVE FORCES ANALYSISPART 06: MARKET SEGMENTATION BY TYPE

PART 07: CUSTOMER LANDSCAPEPART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORKPART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDSPART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/af16zt

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More here:
Stroke Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023 - GlobeNewswire

CONWAY, Ark. A Conway man has spent many years living with Multiple Sclerosis, but this year he was also diagnosed with ALS, or Lou Gherigs Disease.

For the Nobles family, every day with their father, Greg, is a treasured moment.

"I was first diagnosed 16 years ago with MS," said Greg Nobles.

Life has been a challenge since, but it was this January when his health began to decline severely.

Greg lost all mobility. After getting treated for his symptoms and not seeing a difference is when neurologists confirmed Greg also suffers from ALS, a nervous system disease weakening muscles with no cure.

"Doctors have never seen a patient with both before, said Bailey Smith, Gregs daughter. Being diagnosed MS first, we got 15 good years with him versus the ALS now.

RELATED: A final fundraiser for the man who boosted the ice bucket challenge

Once active and known as one of the best hairstylist in town, Gregs now homebound hoping for relief from the pain he endures.

"My husband passed away from ALS in 2004, so I know the journey they are going on, said Diana Kirkland, a hair client of Gregs.

Kirkland knew she needed to do something for the Nobles.

She owns Legacy Acres in Conway.

This week shes preparing her space for a fundraising event Friday night to raise money so Greg can receive stem cell therapy, an expensive procedure done in Mexico, but one that will reduce his discomfort.

"If I could just get some mobility back, it's worth it, said Greg.

Greg has already received two rounds of stem cell therapy.

RELATED: Arkansas man raises money for charity by streaming 24-hour gaming session

Fortunately, hes starting to notice relief in his left leg.

But with ALS, hes given 3 to 5 years to live, but with a community coming together to help, his family hopes that love and support will give them more time with him.

"It means everything to us, said Smith. To continue to get stem cells for us, my babies to see my dad keep fighting.

Greg Nobles Fundraising Dinner is at Legacy Acres, 100 Legacy Acres Drive, in Conway on Friday night beginning at 6 p.m.

Everyone is invited. The event will have live music, a silent auction, catered food provided by Catering By S and I.

There will also be a donation table set up for a stem cell therapy fund.

More:
Conway supports man fighting rare double diagnosis of MS, ALS - THV11.com KTHV

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

This post was originally published on Market Research Sheets

See the article here:
Stem Cell Therapy Market Consumer Outlook 2025 | MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. - Market Research Sheets

Aspen Neuroscience, a new biotech company, has raised $6.5 million to develop cell therapies for Parkinsons disease using patients own cells.

The company was co-founded by renowned stem cell scientists Jeanne F. Loring, PhD, and Andres Bratt-Leal, PhD, and initially supported by Summit for Stem Cell, a non-profit organization that provides a variety of services for Parkinsons patients.

Parkinsons hallmark motor symptomsinclude tremor, slowness of movement (bradykinesia), stiffness (rigidity), uncontrollable movements (dyskinesia), and poor balance.

As the disease progresses, patients typically need to gradually increase their dopaminergic therapeutic dose for maximum benefit. Even after that they might sometimes experience reappearance or worsening of symptoms due to diminishing effects of dopaminergic therapy, known was off periods.

Importantly, dopaminergic therapy is delivered to areas of the brain other than the striatum, a key motor control region severely affected in Parkinsons disease. Because of the therapys off-target behavior, patients also may experience side effects such as hallucinations or cognitive impairment.

Aspen wants to combine its expertise in stem cell biology, genomics and neurology and develop the first autologous (self) stem cell-based therapy for Parkinsons disease.

In this type of cell therapy, a patients own cells (usually skin cells) are reprogrammed back into a stem cell-like state, which allows the development of an unlimited source of almost any type of human cell needed, including dopamine-producing neurons, which are those mainly affected by this disorder.

Because these cells are derived from patients, they do not carry the risk of being rejected once re-implanted, eliminating the need for immunosuppressive complementary therapies, which carry serious side effects such as infections and possibly limiting therapeutic potential.

In theory, replacing lost dopaminergic neurons with new stem cell-derived dopamine-producing ones could potentially ease or reverse motor symptoms associated with the disease.

Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinsons disease, Howard J. Federoff, MD, PhD, Aspens CEO, said in a press release.

We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist, Federoff said.

The companys lead product (ANPD001) is undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinsons disease. Aspen experts also are developing a gene-editing treatment (ANPD002) for familial forms of Parkinsons, starting with the most common genetic variant in the GBAgene, which provides instructions to make the enzyme beta-glucocerebrosidase.

The new seed funding round was led by Domain Associates and Axon Ventures, with additional participation from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32, according to the press release.

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

More:
Aspen Neuroscience Receives $6.5M for Parkinson's Stem Cell Therapy - Parkinson's News Today

MELVILLE, N.Y., Dec. 16, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative or the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today feature coverage in the news outlet, IEEE Pulse, a magazine of the IEEE Engineering in Medicine and Biology Society. According to IEEE, it is the worlds largest technical professional organization for the advancement of technology.

To view the IEEE Pulse Magazines article featuring BioRestorative, click here.

The published cover-story article features commentary from Francisco Silva, Chief Scientist and Vice President of Research and Development for BioRestorative, regarding BRTX-100, the Companys lead therapeutic candidate for chronic lumbar disc disease. Once the U.S. Food and Drug Administration (FDA) authorizes the sale of BRTX-100, we would ship it to your doctor, and with a 30-minute procedure the material would be injected into your disc in a 1.5 ml solution, explains Silva. He elaborates on the product, discussing growing and expanding stem cells from the patients bone marrow under hypoxic conditions that mimic those in the normal intervertebral space. We are enriching the cells to be able to survive in this harsh environment, says Silva.

In addition to BRTX-100, the magazine article also highlights BioRestoratives other research pursuit, its ThermoStem program, utilizing brown adipose (fat) derived stem cells to target treatment of metabolic diseases and disorders, like diabetes, obesity and hypertension.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, whether the Company will be able to consummate the private placement and the satisfaction of closing conditions related to the private placement and those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: ir@biorestorative.com

See the original post:
BioRestorative Therapies Featured in IEEE Pulse Magazine's Cover Story About Stem Cell Therapies for Low Back Pain - GlobeNewswire

Aspen Neuroscience, a new San Diego biotech company working on stem cell treatment for Parkinsons disease, has come out of stealth mode and raised $6.5 million to pursue clinical testing for its therapy.

Co-founded by well-known stem cell scientist Jeanne Loring, Aspen Neuroscience proposes creating stem cells from modified skin cells of Parkinsons patents via genetic engineering.

The stem cells, which can become any type of cell in the body, then would undergo a process that makes them specialize into dopamine-releasing neurons.

People with Parkinsons lose a large number up to 50 percent at diagnosis of specific brain cells that make the chemical dopamine.

Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems.

Once these modified skin cells have been engineered to specialize in producing dopamine, they can be transplanted into the Parkinsons patient to restore the types of neurons lost to the disease.

The reason we called it Aspen is because l was raised in the Rocky Mountain states, said Loring. When there is a forest fire in the Rockies, the evergreens are wiped out but the aspens are the fist that regenerate after the burn. So it is a metaphor for regeneration.

Aspen still has a long way to go before its proposed therapy would be available to Parkinsons patients. It has been meeting with the U.S. Food and Drug Administration to provide animal trial data and other information in hopes of getting permission to start human clinical trials.

But the company expects the earliest it would get the go-ahead from FDA to start human trials would be 2021.

Loring has been working on the therapy for eight years. She is professor emeritus and founding director of the Center for Regenerative Medicine at the Scripps Research Institute.

Loring co-founded the 20-employee company with Andres Bratt-Leal, a former post-doctoral researcher in Lorings lab at Scripps.

Joining them as Aspens Chief Executive is Dr. Howard Federoff, former vice chancellor for health affairs and chief executive of the University of California Irvine Health System.

Federoff said the company is the only one pursuing the use of Parkinsons patients own cells as part of neuron replacement therapy.

Aspens proprietary approach does not require the use of immuno-suppression drugs, which can be given when transplanted cells come from another person and perhaps limit the effectiveness of the treatment.

Aspens approach is a therapy that is likely to benefit from the fact that your own cells know how to make the best connections with their own target cells in the brain, even in the setting of Parkinsons disease, said Federoff. So when transplanted it is able to set back the clock on Parkinsons.

In addition to Aspens main therapy, it is researching a gene-editing treatment for forms of Parkinsons common in certain families.

Aspens research work up to now has been supported by Summit for Stem Cell, a non-profit on which provides a variety of services for people with Parkinsons disease.

The new seed funding round was led by Domain Associates and Axon Ventures, with additional participation from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32.

Aspens financial backing, combined with its experienced and proven leadership team, positions it well for future success, said Kim Kamdar, a partner at Domain Associates. Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in peoples lives. We clearly see Aspen as fitting into that category, as it is the only company using a patients own cells for replacement therapy in Parkinsons disease.

Continue reading here:
Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinsons disease - The San Diego Union-Tribune

The Global Stem Cell Therapy Market Set For Rapid Growth, To Reach Around USD 4759.27 Million By 2024Research Report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability.The global Stem Cell Therapy Market report is a systematic study of the globalStem Cell Therapy Marketintroducing the advanced state of affairs in the market as well as schemes that aid in its enlargement in the coming years. The report evaluates several factors determining the market expansion as well as the volume of the whole Stem Cell Therapy Market. The report states the aggressive vendor scenery of the market together with the profiles of some of the leading market players. The most important players in the Stem Cell Therapy Market are also discussed in the report.

This Research will help you grow your Business: [Download free Sample PDF of This Research Report]

Some of the Major Stem Cell Therapy Market Players Are:

The report covers the product contributions, revenue generated, segmentation, and business summarization of the foremost players. The report provides data taking into consideration the latest improvements in the global Stem Cell Therapy Market while estimating the contribution in the market of the most important players in the near future. The report estimates the limitation and power of the leading players via SWOT analysis and assesses their growth in the market. Additionally, the key product categories and segments as well as the sub-segments of the global market are clarified in the report.

The market assessment is also estimated throughout the research as well as concludes the data using Porters five analysis on the market enlargement.Further, the report also scrutinizes the Stem Cell Therapy Market based on the manufactured goods categories and customer segments as well as the development of each segment is calculated over the predicted time.

Request Free research report Brochure @https://www.zionmarketresearch.com/requestbrochure/stem-cell-therapy-market

The report collects information accumulated from various authoritarian organizations to estimate the growth of the segments. Additionally, the study also evaluates the global Stem Cell Therapy Market on the basis of the topography and analyzes the macro- and microeconomic features determining the market expansion in every area. Furthermore, the Stem Cell Therapy Market is classified on the basis of various regions.

The Stem Cell Therapy Market segmented by regions/countries:

Browse Press Release:https://www.zionmarketresearch.com/news/stem-cell-therapy-market

Highlights of Stem Cell Therapy Market Report:

1) Global Stem Cell Therapy Market share & sales assessments on the basis of regional and country level segments.

2) Industry share analysis of the top market players.

3) Strategic recommendations for the new companies.

4) Market forecasts for 5 years of all the mentioned segments, sub segments and the regional markets.

5) Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations).

6) Competitive landscaping mapping the key trends.

7) Company profiles with their strategies, financials, and recent developments.

8) Production Supply chain trends analysis latest technological advancements.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/stem-cell-therapy-market

Objective of Studies:

1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Stem Cell Therapy Market.

2. To provide insights about factors affecting the market growth. To analyse the Stem Cell Therapy Market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

4. To provide country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market.

7. To track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Stem Cell Therapy Market.

Why Trust ZMRs Analytical Insights?

Target Audience of Stem Cell Therapy Market:

Manufacturer / Potential Investors

Traders, Distributors, Wholesalers, Retailers, Importers and Exporters

Association and government bodies

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Go here to read the rest:
Global Stem Cell Therapy Market to Become a Worth US$ 4759.27 Million By 2024 - E-Industry News

In building out its cell therapy manufacturing network, Novartis has established four in-house facilities across the US and Europe.

However, the Swiss drugmaker has also used service providers, for example, by partnering with Germanys Fraunhofer IZI to access chimeric antigen receptor (CAR)-T therapies for use in its first European clinical trials and the early years of commercial sales in the region.

Novartis has taken the outsourcing route in Japan, too, completing the technology transfer for CAR-T therapy Kymriah (tisagenlecleucel) to Kobe-based the Foundation for Biomedical Research and Innovation (FBRI) early this year. FBRI subsequently supported clinical supply in Japan.

However, while the Japanese regulator approved Kymriah in March, it is taking longer to get the cell therapy contract manufacturer ready for commercial supply. At a recent R&D day, Novartis said the contract manufacturer will be commercially ready in the second half of next year.

Work to get FBRI commercially ready is part of a broader effort by Novartis to establish the capacity to support its global cell therapy ambitions. Currently, Novartis lacks that capacity.

Novartis CEO Vas Narasimhan said, We are supply constrained on Kymriah. Its not a demand constraint. Our goal is to work hard to relieve that ... constraint. We continue to be optimistic that Kymriah will reach blockbuster potential within the next five years.

The comment follows a period in which Kymriah, Novartis approved CAR-T, has fallen short of sales expectations. Sales over the first nine months of 2019 totalled around $180m (163m).

Novartis struggles to meet demand for Kymriah reflect the novel challenge of making autologous cell therapies, which are produced by taking a patients own cells, processing them and administering them back into the same patient.

Cell therapies are one of a clutch of emerging modalities and therapeutic concepts that are central to Novartis pipeline plans. Novartis recognises that it needs to match its infrastructure to the changing mix of modalities in its pipeline, as Jay Bradner, president of the Novartis Institutes for BioMedical Research, explained.

Bradner said, Its not enough just to do this in drug discovery, as we have learned. This needs to be a coordinated strategy across the entire enterprise.

That coordinated strategy has led Novartis to add in-house and contract capacity to support plans to introduce more CAR-Ts and CRISPR-edited stem cells in the coming years. Bradner said Novartis is building up scale to accelerate all of these programs[going] forward.

The exact demands Novartis places on that capacity are likely to change in the coming years, with Bradner predicting the future of the field will feature a new way of manufacturing CAR-T cells. One big expected change is the arrival of allogeneic CAR-Ts made from donor cells.

Read more from the original source:
Novartis sets 2020 target for commercial readiness of cell therapy CMO - OutSourcing-Pharma.com

Assessment of the Animal Stem Cell Therapy Market

The latest report on the Animal Stem Cell Therapy Market published by Persistence Market Research (PMR) is a valuable tool for established and upcoming market players to solidify their presence in Animal Stem Cell Therapy Market landscape. Further, by leveraging the real-time and result-driven insights included in the report, readers can formulate effective business strategies to gain an advantage in the competitive nature of the market.

The presented study suggests that the Animal Stem Cell Therapy Market is expected to attain a value of ~US$ XX by the end of assessment period and grow at a CAGR of ~XX% during the forecast period, 2017 2025. The underlying trends, growth opportunities, market drivers, and challenges faced by companies in the Animal Stem Cell Therapy Market are analyzed in detail.

Exciting Prices for New Customers!!!Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.persistencemarketresearch.co/samples/14941

Vital Information Included in the Report:

The competitive landscape chapter of the report provides valuable insights related to the business prospects of some of the leading companies in the Animal Stem Cell Therapy Market. The product portfolio, pricing structure, revenue growth, and footprint analysis of each market players are included in the report.

Important Queries Related to the Animal Stem Cell Therapy Market Addressed in the Report

The dynamics of the Animal Stem Cell Therapy Market across major geographical regions are included in the report and represented in the study. In addition, to provide a frictionless reading experience the data is depicted using informative graphs and other graphical illustrations.

Get Access To TOC Covering 200+ Topics at https://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Customized Report As Per Your Requirements athttps://www.persistencemarketresearch.co/request-customization/14941

What Makes PMR Different?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751E-mail id- [emailprotected]Website: http://www.persistencemarketresearch.com

This post was originally published on Downey Magazine

View post:
Animal Stem Cell Therapy Market Poised to Expand at a Robust Pace Over 2017 2025 - Downey Magazine